iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
135 hedge funds and large institutions have $471M invested in iTeos Therapeutics in 2024 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 33 increasing their positions, 56 reducing their positions, and 19 closing their positions.
206% more call options, than puts
Call options by funds: $2.41M | Put options by funds: $786K
19% more capital invested
Capital invested by funds: $396M → $471M (+$75.5M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 19
1% less funds holding
Funds holding: 137 → 135 (-2)
4.58% less ownership
Funds ownership: 100.99% → 96.41% (-4.6%)
41% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 56
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$12.7M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$9.63M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.67M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$2.54M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$1.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$13.8M |
| 2 |
Morgan Stanley
New York
|
-$6.87M |
| 3 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$4.81M |
| 4 |
AG
Artal Group
Luxembourg
|
-$4.38M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.83M |
ITOS Hedge Fund Activity: Q1 2024 in Review
135 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q1 2024, worth a combined $471M — up 19% from $396M a quarter earlier.
Fund positioning in ITOS was balanced in Q1 2024: 19 funds opened new positions, 19 closed out, 33 added to existing stakes and 56 trimmed.
The largest buyer was Braidwell, opening a new position worth an estimated $12.7M. The largest seller was BVF Inc, exiting entirely with an estimated $13.8M sold.
- 135 institutional investors held iTeos Therapeutics (ITOS) as of Q1 2024, down from 137 in Q4 2023.
- Funds reported $471M of iTeos Therapeutics stock for Q1 2024, up 19% quarter-over-quarter.
- 19 funds opened new iTeos Therapeutics positions in Q1 2024 and 19 closed out, a net change of 0 holders.
- The largest iTeos Therapeutics buyer in Q1 2024 was Braidwell, an estimated $12.7M added.
- The largest iTeos Therapeutics seller in Q1 2024 was BVF Inc, an estimated $13.8M sold.
Based on aggregated 13F filings for Q1 2024.